[go: up one dir, main page]

WO2011131779A1 - Dispositif de distribution de médicament et réservoir à médicament présentant un mécanisme de codage mécanique - Google Patents

Dispositif de distribution de médicament et réservoir à médicament présentant un mécanisme de codage mécanique Download PDF

Info

Publication number
WO2011131779A1
WO2011131779A1 PCT/EP2011/056476 EP2011056476W WO2011131779A1 WO 2011131779 A1 WO2011131779 A1 WO 2011131779A1 EP 2011056476 W EP2011056476 W EP 2011056476W WO 2011131779 A1 WO2011131779 A1 WO 2011131779A1
Authority
WO
WIPO (PCT)
Prior art keywords
interface
coding
cartridge
drug delivery
delivery device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/056476
Other languages
English (en)
Inventor
Richard James Vincent Avery
Joseph Butler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of WO2011131779A1 publication Critical patent/WO2011131779A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M2005/2403—Ampoule inserted into the ampoule holder
    • A61M2005/2407—Ampoule inserted into the ampoule holder from the rear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M5/2455—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic with sealing means to be broken or opened
    • A61M5/2466—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic with sealing means to be broken or opened by piercing without internal pressure increase
    • A61M2005/247—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic with sealing means to be broken or opened by piercing without internal pressure increase with fixed or steady piercing means, e.g. piercing under movement of ampoule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/27—General characteristics of the apparatus preventing use
    • A61M2205/276—General characteristics of the apparatus preventing use preventing unwanted use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/60—General characteristics of the apparatus with identification means
    • A61M2205/6045—General characteristics of the apparatus with identification means having complementary physical shapes for indexing or registration purposes

Definitions

  • Specific embodiments of this disclosure relate to reservoirs, particularly reservoirs containing a medicament. More particularly, the present application is generally directed to a coding system for use with a reservoir and a reservoir holder so as to prevent unwanted reservoir cross use.
  • medicament reservoirs may comprise an ampoule, a cartridge, a vial, or a pouch, and may be used with a medical delivery device.
  • Exemplary medical delivery devices include, but are not limited to syringes, pen-type injection syringes, pumps, inhalers, or other similar injection or infusing devices that require at least one reservoir containing at least one medicament.
  • Medicament reservoirs such as ampoules, cartridges, or vials are generally known. Such reservoirs are especially used for medicaments that may be self administered by a patient.
  • the term "medicament”, as used herein, preferably means a pharmaceutical formulation containing at least one pharmaceutically active compound, wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a DNA, a RNA, an enzyme, an antibody, a hormone or an oligonucleotide, or a mixture of the above- mentioned pharmaceutically active compound, wherein in a further embodiment the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary
  • the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, wherein in a further embodiment the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1 ) or an analogue or derivative thereof, or exedin-3 or exedin-4 or an analogue or derivative of exedin-3 or exedin-4.
  • GLP-1 glucagon-like peptide
  • Insulin analogues are for example Gly(A21 ), Arg(B31 ), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
  • Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl
  • LysB28ProB29 human insulin B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N- myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl- ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y- glutamyl)-des(B30) human insulin; B29-N-( -carboxyheptadecanoyl)-des(B30) human insulin and B29-N-( -carboxyheptadecanoyl) human insulin.
  • Exendin-4 for example means Exendin-4(1 -39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser- Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-lle-Glu-Trp-Leu-Lys-Asn- Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
  • Exendin-4 derivatives are for example selected from the following list of compounds:
  • H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1 -39)-(Lys)6-NH2, H-Asn-(Glu)5 des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1 -39)-(Lys)6-NH2, H-Lys6-des Pro36 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1 -39)-Lys6-NH2,
  • Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin,
  • Somatropine Somatropin
  • Desmopressin Terlipressin
  • Gonadorelin Triptorelin
  • Leuprorelin Buserelin
  • Nafarelin Goserelin.
  • a polysaccharide is for example a glucosanninoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned
  • polysaccharides and/or a pharmaceutically acceptable salt thereof.
  • An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
  • Pharmaceutically acceptable salts are for example acid addition salts and basic salts. Acid addition salts are e.g. HCI or HBr salts.
  • Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion
  • R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1 -C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10- heteroaryl group.
  • R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1 -C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10- heteroaryl group.
  • solvates are for example hydrates.
  • a patient suffering from diabetes may require a certain amount of insulin to either be injected via a pen-type injection syringe or infused via a pump.
  • a patient may load a cartridge containing the insulin into a proximal end of a cartridge holder. After the cartridge has been correctly loaded, the user may then be called upon to select a dose of medicament. Multiple doses may be dosed from the cartridge.
  • the drug delivery device comprises a reusable device
  • the cartridge holder may be disconnected from the drug delivery device and the empty cartridge may be removed and replaced with a new cartridge. Most suppliers of such cartridges recommend that the user may dispose of the empty cartridges properly.
  • the drug delivery device comprises a disposable device
  • the cartridge is empty, the user is recommended to dispose of the entire device.
  • Such known self administration systems requiring the removal and reloading of empty cartridges have certain limitations.
  • a user simply loads a new cartridge into the delivery system without the drug delivery device or without the cartridge having any mechanism of preventing cross use of an incorrect cartridge. That is, the drug delivery device does not have a mechanism for determining whether the medicament contained in the cartridge is indeed the correct type of medicament to be administered by the patient and, therefore, the device does not ensure that only the correct cartridge containing the correct medicament may be properly positioned within the drug delivery device.
  • certain known drug delivery devices do not present a mechanism for determining whether the correct type of medicament within the cartridge should be used with that particular drug delivery system.
  • Some drug delivery devices or systems may use a color coding scheme to assist a user or care giver in selecting the correct cartridge to be used with a drug delivery device.
  • color coding schemes pose challenges to certain users, especially those users suffering from poor eyesight or color blindness: a situation that can be quite prevalent in patients suffering from diabetes.
  • a first cartridge containing a first medicament from a first supplier may fit a medical delivery device provided by a second supplier.
  • a user might be able to properly position or load an incorrect cartridge within the drug delivery device and then dispense an incorrect medicament (such as a rapid or basal type of insulin) into a drug delivery device without being aware that the medical delivery device was perhaps neither designed nor intended to be used with such a cartridge.
  • an incorrect medicament such as a rapid or basal type of insulin
  • a desire to reduce the risk of dispensing an incorrect medicament (or the wrong concentration of the medicament) from such a drug delivery device.
  • the problem to be solved by the present application is to provide an interface and a drug delivery system where the safety of the user is increased.
  • the interface may be a component adapted and arranged for being coupled to the reservoir.
  • the interface may comprise a ring-like or sleeve-like member.
  • the interface may further be configured for being coupled to a needle hub.
  • the interface may comprise a distal end configured for being coupled to the needle hub.
  • the reservoir may comprise a cartridge.
  • the reservoir may comprise a vessel.
  • the interface may comprise a first coding feature.
  • a drug delivery device may comprise a corresponding coding feature.
  • the first coding feature may be configured to cooperate with the corresponding coding feature provided within, preferably on, the drug delivery device so as to position the reservoir within the drug delivery device.
  • an interface configured for coding and positioning a reservoir to a drug delivery device.
  • the reservoir may be configured for containing a medicament.
  • the reservoir may comprise a cartridge or a vessel, for example.
  • the interface may comprise a first coding feature.
  • the first coding feature may be provided on an outer surface of the interface.
  • the first coding feature may be configured to mechanically cooperate with a corresponding second coding feature.
  • the corresponding second coding feature may be provided by the device, preferably on an inner surface of the device. Mechanical cooperation between the first coding feature and the corresponding second coding feature may allow the reservoir to be properly positioned within the drug delivery device.
  • mechanical cooperation between the first coding feature and the corresponding second coding feature may prevent insertion of a reservoir into the device which is not intended for use with the device. Furthermore, mechanical cooperation between the first coding feature and the corresponding second coding feature may help to prevent the reservoir slipping out of the device.
  • the interface may be coupled to the reservoir of the drug delivery device.
  • the interface may be integral to said reservoir.
  • the interface may be configured to allow the reservoir to be properly positioned within a reservoir holder, e.g. a cartridge holder, of the drug delivery device.
  • the reservoir holder may be located between the reservoir and the drug delivery device.
  • the corresponding second coding feature may be provided on the reservoir holder, in particular on an inner surface of the reservoir holder.
  • an interface that allows a reservoir to be used with a drug delivery device is disclosed.
  • the interface may be coupled to the reservoir and a first coding feature may be provided on the interface.
  • the first coding feature may include at least one protrusion and/or at least one groove.
  • the presently disclosed coding feature may extend in any direction. As just one example, it may extend in a longitudinal direction, or an axial direction, or a radial direction, or a transverse direction.
  • the first coding feature may cooperate with a corresponding second coding feature of the drug delivery device so as to properly position the reservoir within the drug delivery device.
  • the corresponding coding feature may include at least one groove and/or at least one protrusion.
  • the coding feature may further include a plurality of similar or different coding features in different combinations.
  • Each of the plurality of coding features may comprise a unique geometrical shape and/or a unique size.
  • the plurality of coding features may comprise a first coding feature.
  • the plurality of coding features may comprise a second coding feature.
  • the first coding feature may cover a first area of the interface.
  • the second coding feature may cover a second area of the interface.
  • the second coding feature may include at least one groove.
  • a corresponding second coding feature of the drug delivery device may include at least one protrusion.
  • the interface may comprise a third coding feature.
  • the interface also includes an alignment feature.
  • the drug delivery device may include a corresponding alignment feature.
  • the alignment feature may be adapted and arranged to mechanically cooperate with the corresponding alignnnent feature provided by the drug delivery device.
  • the alignnnent feature may be located on a flange of the interface.
  • the alignment feature may comprise at least one protrusion.
  • the corresponding alignment feature may comprise at least one ramp provided on the drug delivery device or provided on the reservoir holder of the device.
  • the alignment feature may help to prevent relative rotation between the drug delivery device and the interface. This alignment feature may also help ensure that the coding features are aligned on the mating parts.
  • the first coding feature may comprise a non-circular section.
  • the first coding feature includes at least one ramp.
  • the first coding feature may include a plurality of ramps.
  • the ramp may comprise a face at an angle relative to a transverse plane of the interface.
  • the interface comprises a flange.
  • the first coding feature may be provided along the flange.
  • the first coding feature may extend outwardly from the interface, preferably in an axial direction.
  • the first coding feature may extend outwardly from the flange.
  • the first coding feature is provided on a sidewall of the reservoir.
  • the interface includes a main body.
  • the main body may comprise an engagement member, e.g. a thread.
  • the main body may be configured for receiving a needle hub.
  • the needle hub may be connected to the main body by means of the engagement member.
  • the main body may be coupled to the reservoir.
  • a first coding feature may be provided on the main body.
  • the first coding feature may comprise at least one protrusion and/or at least one groove. When the reservoir is inserted into the drug delivery device, the first coding feature may cooperate with a corresponding second coding feature of the drug delivery device so as to properly position the reservoir within the drug delivery device.
  • the coding feature may comprise at least one shoulder.
  • the shoulder may have a constant or a varying diameter. This shoulder may be continuous.
  • the interface comprises a main body.
  • the main body may be configured to be, permanently or releasably, coupled to the reservoir.
  • the main body may comprise a bore.
  • the bore may be configured to define a diameter.
  • the diameter may be measured to receive the reservoir, in particular a distal end of the reservoir.
  • the first coding feature may include at least one, preferably continuous, shoulder.
  • the shoulder may protrude from the main body.
  • the at least one continuous shoulder comprises a varying diameter.
  • the main body further comprises a thread.
  • the thread may be configured for receiving a needle hub.
  • the interface is representative of the medicament contained within the reservoir.
  • a further aspect relates to a drug delivery system.
  • the system may include a drug delivery device.
  • the drug delivery device may comprise a dose setting mechanism.
  • a cartridge holder may be, preferably releasably, secured to the dose setting mechanism.
  • a cartridge may be contained within the cartridge holder.
  • An interface for securing the cartridge within the cartridge holder may be provided.
  • the interface may include a first coding feature.
  • the first coding feature may include at least one protrusion and/or at least one groove. When the cartridge is inserted into the cartridge holder, the first coding feature may cooperate with a corresponding second coding feature.
  • the corresponding second coding feature may be provided by the cartridge holder.
  • a drug delivery system may be provided.
  • the drug delivery system may comprise a drug delivery device.
  • the drug delivery device may be a pen-type device, preferably a pen-type injector.
  • the drug delivery device may comprise a dose setting mechanism.
  • the drug delivery device may comprise a cartridge holder.
  • the cartridge holder may be secured to the dose setting mechanism.
  • a cartridge may be contained within the cartridge holder.
  • the drug delivery system may comprise the previously described interface.
  • the first coding feature may be configured to mechanically cooperate with the corresponding second coding feature provided by the drug delivery device, preferably by the cartridge holder of the drug delivery device. Said mechanical cooperation may help to properly position the cartridge into the drug delivery device, in particular into the cartridge holder.
  • the cartridge holder may be removably secured to the dose setting mechanism.
  • the cartridge may be removably contained within the cartridge holder.
  • the drug delivery device may comprise a reusable drug delivery device.
  • the dose setting mechanism comprises a rotating piston rod for expelling a set dose from the cartridge.
  • an interface configured for coding and positioning a reservoir configured for containing a medicament to a drug delivery device
  • the interface comprising a first coding feature.
  • the first coding feature is configured to mechanically cooperate with a corresponding second coding feature provided by the device so as to allow the reservoir to be properly positioned within the drug delivery device.
  • an interface for coding a reservoir to a drug delivery device comprising a first coding feature and a drug delivery device comprising a corresponding coding feature.
  • the first coding feature cooperates with the corresponding coding feature provided within the drug delivery device so as to allow the reservoir to be properly positioned within the drug delivery device.
  • an interface for positioning a reservoir within a drug delivery device comprising a main body coupled to the reservoir and a first coding feature provided on the main body.
  • the first coding feature comprises at least one protrusion or at least one groove.
  • a drug delivery system comprises a drug delivery device comprising a dose setting
  • the drug delivery system comprises the previously described interface.
  • the first coding feature is configured to mechanically cooperate with the corresponding second coding feature provided by the drug delivery device or by the cartridge holder of the drug delivery device so as to properly position the cartridge into the drug delivery device or into the cartridge holder.
  • a drug delivery system comprising a drug delivery device comprising a dose setting mechanism.
  • the system comprises a cartridge holder secured to the dose setting mechanism.
  • the system comprises a cartridge contained within the cartridge holder.
  • the system comprises an interface for properly positioning the cartridge within the cartridge holder, the interface including a first coding feature comprising at least one protrusion or at least one groove.
  • the first coding feature cooperates with a corresponding second coding feature of the cartridge holder so as to properly position the cartridge to the cartridge holder.
  • Figure 1 illustrates an exemplary pen-type drug delivery device
  • Figure 2 illustrates a cartridge that may be loaded into a cartridge holder of the pen-type drug delivery device illustrated in Figure 1 ;
  • Figure 3A illustrates a first arrangement of a coding system that may be provided on an interface for use with a cartridge that may be used with a pen-type drug delivery device, such as the drug delivery device illustrated in Figure 1 ;
  • Figure 3B illustrates another arrangement of a coding system that may be provided on an interface for use with a cartridge that may be used with a pen-type drug delivery device, such as the drug delivery device illustrated in Figure 1 ;
  • Figure 4 illustrates another alternative arrangement of a coding system on an interface for use with a cartridge
  • Figure 5A and 5B illustrates another alternative arrangement of a coding system on an interface for use with a cartridge
  • Figure 6 illustrates another alternative arrangement of a coding system on an interface for use with a cartridge
  • Figure 7 illustrates another alternative arrangement of a coding system on an interface for use with a cartridge
  • Figure 8 illustrates a top view of the interface illustrated in Figure 7;
  • Figure 9 illustrates another alternative arrangement of a coding system on an interface for use with a cartridge
  • Figure 10 illustrates one alternative arrangement of an interface partially inserted into a cartridge holder
  • Figure 1 1 illustrates the interface of Figure 10 in a final, properly seated position
  • Figure 12A illustrates another alternative arrangement a coding system on an interface for use with a cartridge
  • Figure 12B illustrates the interface illustrated in Figure 12A in a final, properly seated position
  • FIG. 12C-E illustrates other alternative arrangements of a coding system
  • Figure 13 illustrates another alternative arrangement of a coding system on an interface for use with a cartridge
  • Figure 14 illustrates another alternative arrangement of a coding system on an interface for use with a cartridge
  • Figure 15A illustrates a top view of another alternative arrangement of a coding system on an interface for use with a cartridge
  • Figure 15B illustrates a portion of the top view of the alternative arrangement illustrated in Figure 15A
  • Figure 16 illustrates another alternative arrangement of a coding system on an interface for use with a cartridge
  • Figure 17 illustrates another alternative arrangement of a coding system on an interface for use with a cartridge
  • Figure 18 illustrates another alternative arrangement of a coding system on an interface for use with a cartridge
  • Figure 19 illustrates another alternative arrangement of a coding system on an interface for use with a cartridge
  • Figure 20A-D illustrate one arrangement of a coding system for use with an interface for use with a cartridge
  • Figure 21 A illustrates another arrangement of a coding system on an interface for use with a cartridge
  • Figure 21 B illustrates a top view of the interface illustrated in Figure 21 A
  • Figure 22 illustrates another arrangement of a coding system on an interface for use with a cartridge
  • Figure 23 illustrates another arrangement of a coding system on an interface for use with a cartridge
  • Figure 24 illustrates an interface having an alignment feature for use with a cartridge that may be used with a pen-type drug delivery device, such as the drug delivery device illustrated in Figure 1 ;
  • Figure 25 illustrates the interface illustrated in Figure 24 attached to a distal cartridge holder portion (without a cartridge);
  • Figure 26 illustrates the interface illustrated in Figure 24 attached to the distal cartridge holder portion with a cartridge and a double ended needle
  • Figure 27A illustrates an interface having an alignment feature and coding features for use with a cartridge that may be used with a pen-type drug delivery device, such as the drug delivery device illustrated in Figure 1 ;
  • Figure 27B illustrates a distal cartridge holder portion that may be used with the interface illustrated in Figure 27A;
  • Figure 28 illustrates a top view of an alternative configuration of alignment features and coding feature that may be located on the interface
  • Figure 29 illustrates an alternative arrangement of a coding system comprising a plurality of interfaces
  • Figure 30A illustrates one arrangement of a coding system for use with an interface for use with a cartridge
  • Figure 30B illustrates one arrangement of a coding system for use with an interface comprising an alignment feature for use with a cartridge
  • Figure 31 A illustrates yet another embodiment of a coding system for a drug cartridge
  • Figure 31 B illustrates yet another embodiment of a coding system for a drug cartridge
  • Figure 32 illustrates yet another embodiment of a coding system for a drug cartridge
  • Figure 33 illustrates the coding system of Figure 32 in a first position in a drug delivery device
  • Figure 34 illustrates an alternative reservoir that may be used with any interface disclosed in the present application.
  • a drug delivery device 100 in the form of a pen- type syringe.
  • This drug delivery device 100 comprises a dose setting mechanism 102, a cartridge holder 104, and a removable cap 106.
  • a proximal end 105 of the cartridge holder 104 and a distal end 103 of the dose setting mechanism 102 are removably secured together.
  • the pen-type syringe may comprise a re-usable or a disposable pen- type syringe. Where the syringe comprises a reusable device, the cartridge holder 104 and the dose setting mechanism 102 are removably coupled together. In a disposable device, they may be permanently coupled together.
  • the dose setting mechanism 102 comprises a piston rod 109, such as a threaded piston rod that rotates when a dose is injected.
  • a double ended needle assembly is attached to a distal end 108 of the cartridge holder 104.
  • the distal end of the holder 104 comprises a thread 121 (or any other suitable connecting mechanism such as a snap lock, snap fit, form fit, or bayonet lock mechanism) so that the needle assembly may be removably attached to the distal end of the holder 104.
  • the removable cap 106 can be releasably retained over the cartridge holder 104.
  • An inner cartridge cavity 1 1 1 defined by the cartridge holder 104 is dimensioned and configured to securely receive and properly retain a cartridge 120.
  • the cartridge 120 may comprise an integral cartridge assembly wherein the assembly is inserted directly into the drug delivery device 100 without the use of a separate cartridge holder 104.
  • Figure 2 illustrates a perspective view of the cartridge 120 that may be used with the drug delivery device 100 illustrated in Figure 1 .
  • the cartridge 120 includes a generally tubular barrel 122 extending from a distal end 130 to a proximal end 132.
  • the distal end 130 is defined by an inwardly converging shoulder 131 .
  • the cartridge 120 includes a smaller diameter neck 126 and this neck 126 projects distally from the shoulder 131 of the barrel 122.
  • this smaller diameter neck 126 is provided with a large diameter annular bead 123 and this bead extends circumferentially thereabout at the extreme distal end of the neck 126.
  • a pierceable seal or septum 133 is securely mounted across the open distal end defined by the neck 126.
  • the seal 121 may be held in place by a metallic sleeve or ferrule 124. This ferrule 124 may be crimped around the circumferential bead at the distal end of the neck 126.
  • the medicament 125 is pre-filled into the cartridge 120 and is retained within the cartridge 120, in part, by the pierceable seal 133, the metallic sleeve 124, and a stopper 128.
  • the stopper 128 is in sliding fluid-tight engagement with the inner tubular wall of the barrel 122.
  • Axially directed forces acting upon the stopper 128 during dose injection or dose administration may urge the medication 125 from the cartridge 120 through the double ended needle mounted onto the distal end 130 of the cartridge holder 104 and into the injection site.
  • Such axially directed forces may be provided by the piston rod, such as the rotatable piston rod 109 of the drug delivery device illustrated in Figure 1 .
  • a label 129 or some other similar type printed matter is provided along an outer surface of the cartridge 120.
  • This label 129 may be used to provide indicia relating to the cartridge contents, the medicament 125 contained within the cartridge 120, manufacturing and/or lot information related to the assembly and filling of the cartridge 120 along with expiration data.
  • the coding methods and systems disclosed herein may be provided either on the cartridge 120 or on the label 129 provided along this outer surface of the cartridge 120.
  • the cartridge 120 comprises a molded cartridge that can be directly inserted into the drug delivery device 100
  • the presently disclosed coding systems and methods may be integral with such molded cartridges.
  • the presently disclosed coding systems and methods may be provided by way of an element that is separate and apart from either the cartridge 120, the cartridge holder 104, or the dose setting mechanism 102 illustrated in Figure 1 .
  • a portion of the cartridge holder 104 defining the cartridge holder cavity 1 1 1 is of substantially uniform diameter represented in Figure 1 by Di 134.
  • This diameter Di 134 is preferably slightly greater than the diameter D 2 136 of the cartridge 120.
  • the interior of the cartridge holder 104 includes an inwardly-extending annular portion or stop that is dimensioned to prevent the cartridge 120 from moving within the cartridge holder 104. In this manner, when the cartridge 120 is loaded into the cavity 1 1 1 of the cartridge holder 104 and the cartridge holder 104 is then connected to the dose setting member 102, the cartridge 120 will be securely held and properly positioned within the cartridge cavity 1 1 1 .
  • the neck 126 and ferrule 124 of the cartridge 120 are inserted in a proximal to a distal direction into the open proximal end of the cartridge holder 104 with the ferrule 124 eventually passing entirely into the holder 104.
  • the proximal end of the cartridge 120 will typically abut a stop provided by the dose setting member 102.
  • a number of doses of a medicament 125 may be dispensed from the cartridge 120.
  • the cartridge 120 contains a type of medicament 125 that must be
  • One such medicament 125 is insulin and another such drug is human growth hormone.
  • the movable piston or stopper 128 is retained in a first end or proximal end of the cartridge 120 and receives the axial force created by the piston rod 109 of the dose setting mechanism 102.
  • the dose setting mechanism 102 comprises a dose setter 1 17 at the proximal end of the dose setting mechanism 102.
  • the dose setter 1 17 is rotated to set a dose and in this manner translates in a proximal direction away from the attached cartridge holder 104.
  • the user attaches the needle assembly comprising the double ended needle on the distal end of the cartridge holder 104. In this manner, the needle assembly pierces the septum 133 of the cartridge 120 and is therefore in liquid communication with the medicament 125.
  • the user pushes on the dose setter 1 17 to inject the set dose and the dose setter translates and rotates in a opposite direction back towards and into the drug delivery device 100.
  • the same dose setting and dose administration procedure is followed until the medicament 125 in the cartridge 120 is expended and then a new cartridge must be loaded in the device 100. If the drug delivery device 100 comprises a reusable drug delivery device, to exchange an empty cartridge 120, the user is called upon to remove the cartridge holder 104 from the dose setting mechanism 102.
  • Figure 3A illustrates a first arrangement of an interface 204 comprising a coding feature 200 for use with a cartridge or cartridge holder that may be used with a pen-type drug delivery device, such as the drug delivery device 100 illustrated in Figure 1 .
  • the coding feature 200 illustrated in Figure 3A may be provided on a cartridge label, a cartridge holder, a dose setting member, an integral or moldable cartridge, or on an element that is separate from the cartridge or cartridge holder.
  • the proposed coding feature 200 helps to ensure that a proper cartridge is used with a proper cartridge holder and, therefore, a preferred drug delivery device. If the coding features do not correctly mate or mesh with corresponding coding features to properly position the cartridge, the user of the drug delivery device may become quickly aware that the cartridge and, hence, the drug contained within the cartridge, is not a cartridge that is intended to be used with a particular drug delivery device.
  • the proposed coding feature methods and systems also tend to help to ensure that a proper cartridge holder is used with a proper drug delivery device. If the coding features do not correctly mate or mesh with corresponding coding features to properly position the cartridge, the user of the drug delivery device may become quickly aware that the cartridge holder and, hence, the drug contained within the cartridge holder, is not a cartridge holder that that is intended to be used with a particular drug delivery device.
  • a first coding feature 200 may comprise one or more separate coding elements 201 a-c and these elements 201 a-c may be located on a flange 202 of an interface 204.
  • the interface 204 may take the form of a single flange or plate 202.
  • the interface 204 may take the form of a longitudinal wall such as a ring, as illustrated in Figure 3B. Coding features 200 may then be located on a flange or a sidewall of the interface 204, or on both as illustrated.
  • Such an interface 204 may be applied to a distal end of a cartridge, such as a glass cartridge or a molded cartridge.
  • the interface 204 and coding features 200 may be provided at a different location within the drug delivery device, such as the device 100 illustrated in Figure 1 .
  • the interface 204 may be provided along the ferrule 124 of the cartridge 120, along the label 129, somewhere along the cartridge holder 104, within the drug delivery device 100, or on the cap 106.
  • the interface 204 may be provided along a cartridge sidewall such as directly on a cartridge sidewall or on an additional component connected to the cartridge sidewall.
  • Figure 3B illustrates an alternative interface 1200 that may be used to code a cartridge holder to a drug delivery device wherein the interface 1200 comprises a sleeve or a ring.
  • a first coding feature 1202 may comprise one or more separate coding elements 1204, 1206, and 1208 and these elements may be located on an outer surface 1203 of an interface 204.
  • each coding element 1204, 1206, and 1208 has a unique geometrical configuration.
  • each coding element 1204, 1206, and 1208 may be spaced equally (90 degrees) from one another however alternative arrangements may also be used.
  • Figure 4 illustrates an alternative arrangement of an interface 220.
  • the interface 220 illustrated in Figure 4 may comprise a cylindrically shaped cap comprising a main body 226.
  • This main body 206 may define a centrally located aperture 228, which is described in greater detail herein.
  • This aperture 228 extends from a proximal end 230 to a distal end 232 of the main body 226.
  • the aperture 228 is placed over the ferrule located at the distal end of a cartridge, such as cartridge 120.
  • this main body 228 has a diameter D 2 214 that is slightly larger than the diameter of the ferrule 124 of the cartridge 120.
  • the interface 220 further comprises an axially extending wall 225 that extends from a flange 222 located near the proximal end of the main body 226. This axially extending wall 225 extends towards the distal end of the main body 226.
  • aperture 228 is sized or configured so that, when the interface 220 is snapped over the ferrule of a cartridge, such as the cartridge 120 illustrated in Figure 2, the aperture 228 can expose a portion of the ferrule 124 of the cartridge 120 and will provide access to at least a portion of the pierceable septum 133 of the cartridge 120.
  • the interface 220 comprises an outer thread and is intended for use with a double ended needle, such as comprised by the needle arrangement 872 illustrated in Figure 26.
  • a needle arrangement 872 may have a hub having an internal thread.
  • an outer surface of the axially extending wall of the main body 226 is provided with an outer thread 236 that receives such a hub of the double ended needle.
  • Such an outer thread 236 could comprise a single or a double start outer thread.
  • the piercing distal needle projects through the aperture 228 and into the pierceable seal of the cartridge 120.
  • the interface 220 may be provided without an outer thread.
  • a first coding feature may comprise one or more coding elements.
  • the interface 204 illustrated in Figure 3A comprises a plurality of coding elements 201 a, 201 b, and 201 c.
  • the coding elements 201 a, 201 b, and 201 c may comprise three protrusions.
  • this interface 220 comprises three coding elements 223a, 223a, and 223c. In one arrangement, these coding elements may mechanically code the interface to the cavity 1 1 1 of the cartridge holder 104.
  • these coding elements may mechanically code the interface to another component of the drug delivery device, such as the dose setting member 102 of the drug delivery device 100.
  • these coding elements may mechanically code the interface to a separate component independent of the cartridge 120, the cartridge holder 104, or the drug delivery device 100.
  • the protrusions may cooperate with corresponding indentations within the cartridge holder 104 or drug delivery device 100.
  • the interface 220 comprises three coding elements 223a, 223b, and 223c.
  • the coding elements 223a, 223b, and 223c comprise protrusions.
  • Each of these coding elements 223a, 223b, and 223c comprises a different geometrical shape.
  • coding element 223a comprises a triangular shape
  • coding element 223b comprises a round shape
  • coding element 223c comprises a rectangular shape.
  • Each coding element 223a, 223b, 223c is offset from an adjacent coding element 223a, 223b, and 223c by 90 degrees.
  • protrusion geometries, protrusion configurations, and protrusion locations may also be utilized.
  • the coding elements 223a-c may be of different sizes and shapes, may be offset from an adjacent protrusion or protrusions by the same or varying degrees, or there may be any number of protrusions, grooves, or different features as illustrated herein.
  • Figures 5A and 5B illustrate a coding system for coding two different medicaments.
  • this first interface 227 has a set of three protrusions 229 a-c and this set comprises a rectangle, a half-circle and a triangle.
  • the second interface 231 of this coding system illustrated in Figure 5B comprises three protrusions 242, 244, and 246. Two of these protrusions 244, 246 comprise a triangular shaped protrusion and the third protrusion 242 comprises a rectangular shaped protrusion. Although only certain shapes are shown, it should be understood that the various set of interfaces making up the coding system may comprise any collection of protrusions and/or grooves.
  • each shape may be smaller in one area and larger in another than all of the other shapes in the coding system.
  • Figure 6 illustrates yet another alternative arrangement of an interface comprising a coding feature arrangement.
  • Figure 6 illustrates an interface 250 having a coding feature 252 that comprises a single coding element and this single coding element takes the form of a protrusion 256.
  • This protrusion 256 extends upwardly away from the plate or flange 254 in a longitudinal direction.
  • Figure 6 illustrates the longitudinal coding features as being attached to a flange 254 and not attached to the sidewall of the interface 250, but in alternative embodiments it may be attached to the sidewall.
  • the coding feature 252 illustrated in Figure 6 may also be attached to an interface 204 similar to the one illustrated in Figure 3.
  • Figures 7-8 illustrate other alternative arrangements of interfaces, in which the coding features are orientated in different directions.
  • the interface 260 will have the same cap like structure as the interface 220 illustrated in Figure 4.
  • the interface 260 will comprise a different coding arrangement 264.
  • the interface 260 may comprise one or more protrusions wherein the protrusions 266, 268 extend outwardly from the plate or flange 272 in a radial direction away from the interface main body.
  • the protrusions might extend in a transverse direction, so that each protrusion has parallel sides.
  • Figure 8 illustrates a top perspective view of the interface illustrated in Figure 7. As illustrated in Figure 7 and 8, these protrusions 266, 268 extend radially away from the flange 272, and are attached only to the flange 272 and are not attached to a sidewall of the interface.
  • the protrusions may extend outwardly from a sidewall of the main body. These protrusions 266, 268 do not extend longitudinally in a distal direction towards the distal end of the interface, but they may do so in other embodiments. As those of ordinary skill in the art will recognize, alternative protrusion arrangements may also be utilized. As just one example, the coding features illustrated in Figures 7 and 8 could also be attached to an interface 204 similar to the one illustrated in Figure 3.
  • FIG. 9 illustrates yet another alternative arrangement of an interface 280 for use with a drug delivery device.
  • this interface 280 comprises another cap like structure comprising plurality of asymmetric coding features.
  • the interface 280 comprises both alignment features and asymmetric coding features.
  • the interface 280 comprises two alignment features 284 a, b and two asymmetric coding features 282 a, b.
  • the alignment features 284 a, b provide a means of aligning the interface 280 when the cartridge (and hence the interface 280) are inserted into a cartridge holder.
  • the coding 282 a, b and alignment features 284 a, b illustrated in Figure 9 could also be attached to an interface 204 similar to the one illustrated in Figure 3.
  • alternative coding feature and alignment arrangements may also be used where the various protrusion can vary in height, length, width and/or orientation.
  • a corresponding second coding feature may be located within the drug delivery device, for example, in the cavity 1 1 1 of the cartridge holder 104.
  • a corresponding second coding feature may be located directly in the cavity of the drug delivery device 100.
  • the interface may be snapped over the distal end 108 of the cartridge 120 such that the interface form fits or snaps around the ferrule 124 of the cartridge. It should be understood that the interface may also be secured to the cartridge 120 by any suitable means known in the art.
  • the interface may comprise a flexible material so that the interface deforms when it is passed over the distal end of the cartridge 120.
  • Figure 10 illustrates an interface 306 that is mounted onto a cartridge 301 and then partially inserted into the cartridge holder.
  • Figure 1 1 illustrates this interface 306 in a fully seated or inserted position within the cartridge holder 292, with the distal end of flange 308 on interface 306 abutting the proximal end of the inwardly directed flange 310 on cartridge holder 292.
  • Figure 10 illustrates a perspective view of a distal end of a modified cartridge holder 292 that could be used with an interface 306 comprising a coding scheme consisting of a first coding feature, for example a first and a second protrusion 294, 296.
  • the proximal end of the cartridge holder 292 would include a similar releasable connection mechanism (e.g., thread, snap lock, snap fit, bayonet lock, etc.) as the cartridge holder 104 illustrated in Figure 1 .
  • the cartridge holder 292 now comprises a bore located near the distal end of the holder 292.
  • the distal end of this modified cartridge holder 292 defines a second coding feature, for example a first and a second cut out 302, 304. Cut outs 302, 304 are so configured that, when a cartridge with a correctly coded interface is inserted into a proximal end of the cartridge holder 292, the interface properly meshes the radially extending protrusions 294, 296 of the interface to an end position located at the distal end of the holder 292.
  • FIG. 12A and 12B illustrate yet another arrangement of an interface 320, in which there is more than one coding feature on the interface.
  • the interface 320 is illustrated as being partially inserted into a proximal end of a cartridge holder 322.
  • Figure 12A illustrates an interface 320 in the form of a sleeve having a side wall 324.
  • This side wall 324 is generally smooth and may be provided with a coding feature 326 comprising a plurality of radially extending protrusions 328, 330.
  • the protrusions 328, 330 may be positioned at different axial or circumferential locations along an outer surface of the main body of the interface 320.
  • These protrusions 328, 330 are configured to mate with a first and a second corresponding protrusion such as an inner ridge or blocking feature 332, 334 provided along an inner surface of the cartridge holder 322.
  • these protrusions 328, 330 may be configured to mate with a first and a second corresponding protrusion provided by a drug delivery device or a separate component, separate and apart from either the cartridge holder or the drug delivery device.
  • a cartridge might fit into an incorrect device.
  • an exemplary coding system 336 for three drugs is illustrated in Figures 12C-E. This coding system 336 may be used to code three drugs where the coding system 336 only comprises one coding feature.
  • Figure 12C illustrates an interface 342 similar to the interface of Figure 12A where the interface 342 comprises a form in the shape of a cap having a side wall 344.
  • This side wall 344 is generally smooth and may be provided with a coding feature 346 comprising a radially extending protrusion 328. As illustrated in the other coding schemes illustrated in Figures 12D and 12E, this protrusion may be positioned at different axial or
  • the protrusion 368 of the coding feature of Figure 12D is positioned higher in a distal direction along the interface 362 than the protrusion 328 of interface 342.
  • the protrusion 388 of the interface 382 is positioned higher than the protrusion 368 of Figure 12D. Similar to the coding arrangement illustrated in Figures 12A-B, these protrusions 328, 368, and 388 are configured to mate with a first corresponding protrusion provided as an inner ridge or blocking feature provided along an inner surface of the cartridge holder.
  • one of the coding features may be located earlier in the assembly direction and one is located later.
  • the coding feature for a first drug contained within Figure 12C is located earlier in the assembly direction than for the drug contained within Figure 12D and this is located earlier in the assembly direction than the drug contained within Figure 12E.
  • This coding might prevent the interface for drug in Figure 12E fitting into the device for drug contained in Figure 12C.
  • the interface for drug in Figure 12C could still fit into the holder for drug Figure 12E.
  • all drugs can be prevented from fitting into an incorrect device.
  • a first coding feature may include at least one circular shoulder 402.
  • the interface 400 comprises a sleeve 404 comprising a first continuous circular shoulder 402.
  • the shoulder 402 may be coded to the cavity 1 1 1 of the cartridge holder 104 or may be coded to the drug delivery device 100 by means of the diameter and/or location of the shoulder 402.
  • a drug contained within a reservoir might fit into an incorrect device.
  • a large shoulder 402 would not fit into a device intended for a smaller shoulder, but a small shoulder would fit into a device intended for a larger shoulder.
  • Similar problems might exist where an interface is coded only by the axial position of a shoulder.
  • a system is coded by more than one dimension, a plurality of drugs can be prevented from fitting into an incorrect device.
  • one drug might have a shoulder with a small diameter located a small distance from the end face, and another drug might have a larger diameter shoulder located a larger distance from the end.
  • the volume swept by the coding for one drug during assembly must not be completely covered by the volume swept for another drug.
  • a shoulder 402 may be secured to the sleeve 404 a distance L from a distal end of the interface 400.
  • the interface shoulder 400 may have a single constant outer diameter 0 D as illustrated in Figure 13.
  • this sleeve 404 could be applied to a surface of a cartridge glass, a ferrule, a label, a separate component interface on a sidewall of a cartridge, a cartridge holder, the drug delivery device body, or a drug delivery cap.
  • the shoulder 402 may be integrally molded to either a cartridge or a cartridge holder.
  • a corresponding second coding feature such as a groove or a shoulder, may be located in the cavity 1 1 1 of the cartridge holder 104 or elsewhere within the drug delivery device 100.
  • the shoulder 402 may alternatively be secured to a main body of an interface in the form of a cap or sleeve, similar to the cap like interface illustrated in Figure 4.
  • Figure 14 illustrates an interface 410 having a shoulder 412 similar to that of interface 400 illustrated in Figure 13.
  • the shoulder 412 may be secured to the sleeve a distance L from a distal end of the interface 410 and the interface shoulder 412 may have a single constant outer diameter 0 D as illustrated.
  • a protrusion is coded in two dimensions, for example by its radial and circumferential extents.
  • Such an interface arrangement 420 is illustrated in Figures 15A, where an interface is overlaid on an incorrect mating part 421 .
  • Mating part 421 may be provided on a drug delivery device, a cartridge or reservoir holder or as a component part separate from the drug delivery device.
  • Figure 15B shows a detailed view of the coding protrusion 460 on the mating part 421 and the coding indentation 450 on the interface.
  • a drug might fit into an incorrect device.
  • a coding protrusion 460 would fit into an indentation 450 with a larger circumferential extent, or with a larger radial extent.
  • drugs can be prevented from fitting into an incorrect device.
  • coding protrusion 460 does not fit into the coding indentation 450 on the interface.
  • the protrusion 460 fits into indentation in the circumferential direction, its radial extent is too large.
  • a coding feature for one drug must be smaller in one dimension and larger in another than corresponding features for other drugs. In other words, the coding feature must cover an area that is not completely covered by the area of any other protrusions that might be used at the same location for different medicaments.
  • the proposed interface systems may comprise a plurality of shoulders 600, so that coding is achieved using more than one coding feature on the interface.
  • Such an interface may comprise a variety of different diameters and/or widths and at various locations.
  • Figure 16 illustrates an interface 600 comprising a coding feature 606 that comprises two shoulders 602, 604 wherein each shoulder 602, 604 has a different diameter but a similar width.
  • the first shoulder 602 comprises a first width W1 and has a first diameter D1 .
  • This first shoulder 602 extends a distance L1 from a proximal end of the interface 600 to a distal end of the interface 600.
  • the second shoulder 604 of the coding feature 606 comprises a second width W2 and a second diameter D2 and extends a distance L2 from the proximal end to a distal end.
  • the width W, diameter D, and length L can be varied, so that no drug fits into an incorrect device.
  • the volume swept by the coding for one drug during assembly must not be completely covered by the volume swept for another drug.
  • alternative shoulder arrangements having a plurality of shoulders of varying widths, diameters, and geometric locations along the interface may also be used.
  • Figure 17 illustrates a similar interface coding arrangement for an interface 620 comprising a coding scheme 626 comprising a first and a second shoulder 622, 624, respectively.
  • the first shoulder 622 comprises a first width W1 and has a first diameter D1 .
  • This first shoulder 622 extends a distance L1 from a proximal end of the interface 620 to a distal end of the interface 620.
  • the second shoulder 624 of the coding feature 626 comprises a second width W2 and a second diameter D2 and extends a distance L2 from the proximal end to a distal end.
  • alternative interface arrangements having a plurality of shoulder of varying widths, diameters, and geometric locations along the interface may also be used.
  • Figures 18-23 show alternate coding feature arrangements.
  • the interface 640 comprises a first coding feature 642 that includes one or more indentations or grooves.
  • the coding feature 642 comprises a first indentation 644, a second indentation 646, and a third indentation 648.
  • Each indentation 644, 646, 648 comprises a unique or proprietary geometric shape.
  • These indentations 644, 646, 648 may reside along a flange 641 of the interface 640, but alternatively, the indentations 644, 646, 648 may be cut into the sidewall of the main body.
  • the corresponding coding or mating feature or features could comprise a corresponding protrusion or protrusions that mesh or that interface with the one or more indentations or grooves. Such indentations and/or grooves may be located within the cavity 1 1 1 of the cartridge holder 104 or drug delivery device 100.
  • the coding features illustrated in Figure 18 could also be attached to an interface 204 similar to the one illustrated in Figure 3.
  • the interface 660 comprises a first coding feature 662 comprising a protrusion 664 formed around an indentation 666. Again, such a coding feature 662 may reside on an interface 204 similar to the one illustrated in Figure 3.
  • Such a protrusion 664 may be utilized to increase the length and robustness of the coding features 662.
  • longer coding (or more strictly longer overlap between coding on the mating parts) can be more effective at preventing errors.
  • the longer the coding the more an incorrect cartridge will protrude from the cartridge holder, and either be more obvious to the user, or prevent fastening of the holder to the device. Tolerances may reduce the protrusion (for example, a short cartridge in a long cartridge holder), so longer coding may be needed where tolerances are large.
  • the first coding feature may comprise a combination of both protrusions and indentations in a number of different configurations.
  • FIGS 20 a-d illustrate one exemplary coding system 680 comprising a plurality of interfaces 682 a-d.
  • Such a system of interfaces 682 a-d may be used for coding a plurality of different medicaments.
  • the coding system 680 may be used to code at least four different types of medicaments.
  • This coding system 680 utilizes a combination of at least one protrusion and at least one groove or recess.
  • each coding location has either an indentation or a protrusion, which ensures a large difference in the height of coding features at each location.
  • This combination of coding protrusion and groove features may be spaced an equal distance around the circumference of the interface 682 a-d.
  • these coding features are equally spaced around the outer circumference of the interface 682 a-d.
  • these coding features are spaced approximately by 120 degrees from each other around the outer circumference of the respective interface 682 a-d.
  • this first interface 682a comprises a coding feature 684 in the form of three radial protrusions 686 a-c.
  • the first protrusion 686a is spaced 120 degrees from the second protrusion 686b which is spaced 120 degrees from the third protrusion 686c.
  • the interface 682c comprises a coding feature 688 comprising a first groove 690a and a second groove 690b and a first protrusion 690c.
  • the first groove 690a is spaced 120 degrees from the second groove 690b which is spaced 120 degrees from the first protrusion 690c.
  • an arrangement of protrusions and grooves may be used to code four different medicaments.
  • alternative coding systems of different shapes, geometries, and/or circumferential arrangements may also be utilized.
  • an interface may comprise a first coding feature that may be a non-circular coding feature and that is coded by its geometric shape.
  • Figure 21 A illustrates an interface 700 comprising a coding feature 702 located on the outer edge of the plate or flange 702 in a transverse plane.
  • the non- circular coding may form part of the interface main body itself.
  • a top view of such a coding feature is illustrated in Figure 21 B.
  • FIG. 22 illustrates yet another embodiment of an interface 720 comprising a first coding feature 722.
  • the first coding feature 722 comprises one or more ramps 724, or in other words one or more faces that are angled relative to a transverse plane.
  • the ramp 724 may extend upwardly from a proximal end of the interface 720.
  • a corresponding ramp-shaped second coding feature may be included in the cavity 1 1 1 of the cartridge holder 104 or drug delivery device 100.
  • the coding feature for one drug may cover an area in a longitudinal plane that is not completely covered by the area of coding features for other medicaments.
  • Figure 23 illustrates yet another embodiment of an interface 730 comprising a first coding feature, somewhat similar to the coding features illustrated in Figure 22.
  • the first coding feature 732 comprises a first ramp 734 and a second ramp 736 directed in an opposite directions.
  • the first ramp 734 extends upwardly from a proximal end of the interface 730 in a first direction "A" and the second ramp 736 extends upwardly from the proximal end in a second opposite direction "B".
  • a corresponding ramp-shaped coding feature may be included in the cavity 1 1 1 of the cartridge holder 104 or drug delivery device 100.
  • an interface 804 may be provided with at least one alignment feature 824.
  • the alignment feature 824 is provided along a flange 802 and comprises a generally rounded rectangular shape having an outer diameter D3 814.
  • the alignment feature 824 comprises a single protrusion that is directed radially outwards away from the main body of the interface 804.
  • the protrusion 824 when mounted onto a cartridge, the protrusion 824 extends beyond an outside diameter of a cartridge, such as diameter D 2 136 of cartridge 120 ( Figure 2).
  • the interface 804 is intended for use with a cartridge holder similar to the cartridge holder 104 of Figure 1 but somewhat modified.
  • Figure 25 illustrates a cross-sectional view of a distal end 852 of a modified cartridge holder 850 that could be used with the interface 804 having a single protrusion feature 824.
  • the proximal end (not shown) of the cartridge holder 850 would include a similar releasable connection mechanism (e.g., thread, snap lock, snap fit, bayonet lock, etc.) as the cartridge holder 104 illustrated in Figure 1 .
  • the cartridge holder comprises a bore 854 located near the distal end 852 of the holder.
  • an inner wall 856 of the modified cartridge holder 850 defines a ramp 858 having a predefined ramp projection around an inner circumference. This ramp 858 is so configured that, when a cartridge with a correctly coded interface 804 is inserted into a proximal end of the cartridge holder 850, the ramp 858 guides the radially extending protrusion 824 of the interface 804 to an end alignment position 860 located at the distal end 852 of the holder 850.
  • the alignment feature 824 cooperates with the ramp 858 until the interface resides in a final alignment position 860.
  • the alignment feature 824 will travel along the ramp projection around the circumference of the cartridge. This alignment feature 824 will eventually align the cartridge 820 within the cartridge holder 850 with the alignment feature 824 eventually residing in the final alignment position 860.
  • the insertion force required to align the interface 804 (and hence the cartridge) within the cartridge holder 840 can be increased or decreased.
  • the alignment feature 824 may help a user align coding on the cartridge 820 with corresponding coding on the cartridge holder 850.
  • the coding may include any of the coding features herein discussed.
  • One advantage of using the interface 804 is that the cooperation between the alignment feature 824 and corresponding ramp 858 may prevent the interface 804 (and, hence, the cartridge 820) from unwanted rotation within the cartridge holder 850 once properly inserted. That is, the alignment feature 824 may prevent unwanted rotation of the interface 804 when a double ended needle is either attached or removed from the distal end of the interface 804.
  • Figure 25 illustrates the alignment feature 824 in the final alignment position 860 (the cartridge has been omitted for clarity) where the distal end 812 of the interface 804 is allowed to pass through the cartridge holder bore 854.
  • Figure 26 illustrates schematically certain relevant parts of the drug delivery device with a needle assembly mounted onto the interface arrangement 804 illustrated in Figure 24.
  • cartridge 820 has a neck with a flange against which a rubber membrane is secured by a ferrule 825 beaded under the flange.
  • the interface 804 may be passed with its bore over a bead 823 and pressed down to make the protrusion pass the ferrule 825 and grip under the lower beaded edge of this bead.
  • Other methods of securing the interface 804 to the cartridge may also be used.
  • a needle arrangement 872 comprises a tubular skirt 870 having an internal thread to be screwed onto the outer thread of the interface 804 with its needle 874 piercing the membrane and projecting into the opening of the neck part of the cartridge 820. This is just one arrangement of how the proposed interface systems may be used to align the cartridge 820 within the cartridge holder 850.
  • the interface 804 and ramp 858 cooperates so as to allow the proper positioning of an acceptable cartridge 820.
  • the interface 804 and ramp 858 will not cooperate and will, therefore, prohibit an incorrect cartridge from being properly inserted into or properly positioned within the drug delivery device.
  • the coding feature (such as a projection, a plurality of projections, or projection arrays) may be provided along a different portion of the cartridge 820.
  • the coding feature could be provided along the tubular member of the cartridge 820 or, alternatively, towards the proximal end of the cartridge 820.
  • the coding features may be provided on an interface that is illustrated in the various figures herein or, alternatively, on a cartridge label, a cartridge holder, a dose setting member, an integral or moldable cartridge, or an element that is separate from the cartridge or cartridge holder.
  • the alignment feature 824 on the interface 804 is shown as a single protrusion, the alignment feature 824 could comprise an indentation that matches a corresponding protrusion located on the internal wall of the cartridge holder 850.
  • the alignment features 824 illustrated in Figures 24-26 may be provided on an interface similar to the one that is illustrated in Figure 3 or, alternatively, on a cartridge label, a cartridge holder, a dose setting member, an integral or moldable cartridge, or an element that is separate from the cartridge or cartridge holder. In one alignment arrangement, more than one protrusion or indentation around the interface circumference may also be provided.
  • Figure 27A illustrates an alternative arrangement of an interface 904 having both an alignment feature 924 for use with a cartridge, such as the cartridge illustrated in Figure 2, as well as at least one coding feature 200. More specifically, the interface 904 may be snapped over the distal end 108 of the cartridge such that it fits around the ferrule of the cartridge and thereby provides a mechanical coding to the cartridge.
  • the interface 904 shown in Figure 27A comprises a cylindrically shaped main body 906 defining a centrally located aperture 908.
  • the flange 902 is provided with the at least one alignment feature 924.
  • interface 904 further comprises at least one coding feature 900 comprising a first and a second protrusion 901 a, 901 b.
  • This coding feature 900 may allow the interface 904 to be mechanically coded to the inner wall of the cartridge holder or the drug delivery device.
  • the coding feature 900 comprises the first and a second radial protrusion 901 a, 901 b that extend both axially away from the main body 906 as well as in a distal direction.
  • alternative arrangements may also be used.
  • Figure 27B illustrates a cross-sectional view of a distal end of a modified cartridge holder 950 that could be used with the interface 904 illustrated in Figure 27A.
  • This cartridge holder 950 comprises a bore 960 located near the distal end 955 of the holder 950.
  • an inner wall of the cartridge holder 950 defines a ramp 970 having a profile for use with an interface having a single protrusion and a first and second coding feature.
  • This ramp 970 is so configured that, when a cartridge with a correctly coded interface is inserted into a proximal end of the cartridge holder 905, the ramp 970 may guide the radially extending alignment interface 924 of the interface 904 illustrated in Figure 27A to an end alignment position 980 located at the distal end 955 of the holder 950. In this manner, when a cartridge carrying the interface 904 is inserted into the cartridge holder 950, the alignment feature 924 cooperates with the ramp 970 until the interface 904 resides in the final alignment position 980.
  • Ramp 970 is also configured to guide the coding features 900 into corresponding coding receiving areas 990.
  • the interface 904 is illustrated as being coupled around the ferrule to the distal end of a cartridge, alternative interface arrangements may also be used.
  • the alignment feature 924 and/or coding 900 may be added to an interface that is provided at another location, such as a ring around a sidewall of the cartridge.
  • the coding 900 may comprise mechanical features that mate with each other, or it may be read electronically.
  • the interface may take the form of ridges or grooves provided along the cartridge glass or moulding.
  • the ferrule itself of the cartridge may be provided with an interface that cooperates with an inner surface of the cartridge holder 950.
  • Figures 28-29 illustrate alternative configurations of alignment features and coding features that may be located on an interface, such as interface 904 illustrated in Figure 27A.
  • the coding features may be provided on an interface as illustrated in the various figures herein or alternatively on a cartridge label, a cartridge holder, a dose setting member, an integral or moldable cartridge, or an element that is separate from the cartridge or cartridge holder.
  • the interface comprise three protrusions 962 a-c, and the size of each coding feature may be different from at least one of the others.
  • One of the features may be used as an alignment feature 924, and may be located at any angle from one or more coding features 900.
  • the alignment feature 924 and coding features 900 may be identical. Alternatively, they may comprise unique shapes and/or sizes.
  • the alignment feature 924 is longer than the coding features. As illustrated, the long feature will only fit into a long slot that may be provided in the cartridge holder or the drug delivery device, this feature and slot combination so fixing the orientation of coding on the cartridge relative to coding on the pen.
  • Figure 28 illustrates an alignment feature 962a that has a certain width represented by W1 and a certain radial extension represented by R1 .
  • the interface further comprises a first coding feature 962b and a second coding feature 962c.
  • the first coding feature 962b has a width W2 and has a radial extension R2.
  • the second coding feature 962c has a width W3 and has a radial extension R3.
  • FIG. 29 a plurality of coding schemes may be used with such features.
  • various different alignment and coding combinations are illustrated in Figure 29. These various different combinations may be utilized by an interface to distinguish among six different medicaments or concentration of medicaments.
  • the alignment feature 962a always resides in the twelve o'clock a position for each of the six interface arrangements illustrated in Figure 29.
  • each of the other locations either has no pin, or at least two pins of two possible radial extents.
  • Alternative arrangements would be possible by varying the axial or circumferential extent of each coding feature 962b, c.
  • alternative alignment and coding feature arrangements may also be utilized so as to properly code a large number of different medicaments.
  • Figures 30A illustrates one exemplary coding system 975 comprising a first and a second interface 977, 979.
  • a system of interfaces 977, 979 may be used for coding a plurality of different medicaments.
  • the coding system 975 may be used to code only two different types of medicaments.
  • the first interface 977 comprises a coding system 980 that utilizes a first groove 981 and a second groove 983.
  • the first groove 981 is positioned at the 12 o'clock position of the interface 977 and is offset or spaced 72 degrees from the second groove 983.
  • the first and second grooves 981 , 983 must match up with corresponding protrusions that are also offset by 72 degrees.
  • the interface 979 comprises a coding arrangement 988 that also comprises a first groove 985 and a second groove 987.
  • the first groove 985 is situated at the twelve o'clock position and the second groove 987 is spaced or offset 144 degrees from the first groove 985.
  • the first and second grooves 985, 987 must match up with corresponding protrusions that are also offset by 144 degrees.
  • an arrangement of these two grooves may be used to code only two different medicaments.
  • alternative coding systems of different shapes, geometries, and/or circumferential arrangements may also be utilized.
  • the coding features illustrated in Figures 30A may be provided on an interface as illustrated in the various figures herein or alternatively on a label, a cartridge holder, a dose setting member, an integral or moldable cartridge, a dose setting member, or an element that is separate from the cartridge or cartridge holder.
  • the number of coding combinations of this system 975 can be increased.
  • this first interface 992 comprises a coding feature 991 in the form of two grooves 994, 996.
  • first coding groove 994 is spaced approximately 72 or 144 degrees from the second groove 996 around the outer circumference of the interface 992 (similar to the first and second groove arrangement of interface 977, 979 in Figure 30A).
  • the first interface arrangement 992 further comprises an alignment feature 998 positioned 180 degrees from the first coding feature 994.
  • the interface 992 could be aligned by making one coding feature unique, e.g. a groove that is smaller than the others.
  • each of the nine interfaces comprises two grooves that are positioned at various offsets and various locations around an outer perimeter of the respective interface.
  • coding features are arranged in a number of fixed positions that are the same for all of the interfaces in the system, but for each interface, coding is only included at selected positions.
  • each of the nine interfaces has the same type of alignment feature as interface 992 and this feature is located at the same location on the interface as alignment feature 998.
  • Figure 31 A illustrates yet another embodiment of a coded drug cartridge.
  • a cartridge 1000 is coded to a cartridge holder 1002 with coding features 1004 located on the sidewall of the cartridge 1000.
  • the coding features 1004 may be applied directly to the cartridge 1000, or on a label.
  • the coding features 1004 may be located on an interface 1006 that is secured to a proximal end of the cartridge 1000.
  • these coding features 1004 may be provided on a label affixed to the cartridge 1000 or perhaps part of a molded cartridge.
  • the protrusion 1012 is a pin for fastening into a groove on the cartridge 1000.
  • the cartridge holder 1002 includes corresponding coding features, grooves 1010, which mate with the coding features 1004 on the cartridge 1000. It should be understood that the coding features 1004 and corresponding coding features 1010 may be replaced with any of the coding features described herein. With such a coding system, the coding features 1004 will provide axial meshing with the corresponding coding features 1010 on the interface 1006. Alternatively, the cartridge 1000 may be coded to the cartridge holder 1002 with the coding feature 1004 but without the radial extending portion 1008. For example, Figure 31 B illustrates one such an arrangement. In this arrangement, the interface 1006b is provided with a plurality of coding features 1010b that mesh in an axial fashion with the corresponding coding features 1010 provided on the cartridge holder 1002b.
  • Figure 32 illustrates yet another embodiment of an interface.
  • the drug cartridge 1 100 is coded directly to a drug delivery device by way of an interface 1 102.
  • the cartridge 1 100 includes the interface 1 102 and this interface 1 102 is secured to a proximal end of the cartridge 1 100.
  • the interface 1 102 may comprise a ring shaped geometry, and may include at least one coding feature.
  • the coding feature comprises a first protrusion 1 104a and a second protrusion 1 104b.
  • the interface 1 102 may comprise an alignment feature, here, the alignment feature comprises two grooves 1 106 a, b.
  • Figure 33 illustrates the coding features of Figure 32 partially connected to a drug delivery device 1 108.
  • the drug delivery device 1 108 may comprise a corresponding coding feature 1 1 10, such as one or more grooves that are geometrically configured to mesh with the first 1 104a and the second protrusions 1 104b provided by the interface 1 107.
  • the coding feature 1 104 and corresponding coding feature 1 1 10 may be replaced with any of the coding features as described herein.
  • the coding features 1 104 pass through the corresponding features 1 1 10 on the drug delivery device, but do not mesh with them when fully inserted.
  • the coding traveling in an axial direction, it may travel in any direction (e.g. axial, helical, or rotational). Therefore, the user will be alerted that the incorrect cartridge has been inserted into the drug delivery device.
  • the interface 1 102 may further include one or more alignment features as previously discussed herein.
  • a first and a second alignment feature 1 106 a, b is provided.
  • the alignment feature or features 1 106 a, b may comprise a groove or a plurality of grooves.
  • the drug delivery device 1 108 may include a corresponding alignment feature or features, such as a protrusion or protrusions.
  • the drug delivery device 1 108 comprises a first and a second protrusion that is geometrically configured to mesh with the first and second alignment features of interface 1 102. It should be understood that any suitable alignment features may be used.
  • alignment feature 1 106 on the interface 1 102 may prevent the coding features 1 104, 1 1 10 from rotating out of alignment with one another.
  • the alignment feature 1 1 12 may be a standard feature for all drugs, while the coding features may vary from one cartridge to another cartridge so as to indicate the type of drug.
  • FIG. 34 illustrates a drug reservoir 1220 comprising a vessel 1222 that contains a medicament 1 124.
  • a stopper 1260 is provided along a distal end of the vessel 1222 and is attached to the vessel 1222 so as to prevent the medicament 1 124 from exiting the vessel 1222.
  • An alignment feature 1228 may be provided on the vessel 1222. In this preferred arrangement, the alignment feature 1228 is provided near an output port 1230 of the vessel 1222 but may also be provided at alternative locations. This output port 1230 has a rigid neck and the alignment feature 1228 is provided along this neck so as to interface with a reservoir holder. Any of the coding features described herein may also be included on the vessel 1222 or on a label applied to such vessel 1222. The disclosed alignment system results in a number of advantages.
  • the proposed alignment system may assist a user to distinguish between medicaments, thereby helping to ensure that a delivery device can only be used with a medicament for which the device is intended. Therefore, with the disclosed coding and alignment system applied to a cartridge, the cartridge may be prevented from being loaded into any other drug by loading a cartridge with an incorrect or unwanted interface.
  • the disclosed cartridge coding and alignment system may prevent a user from completing one or more of the following actions: fully inserting the cartridge into an incorrect cartridge holder or attaching the cartridge and/or cartridge holder onto an incorrect dose setting mechanism.
  • the user is called upon to manually align coding on one part with corresponding features on the other part. Users with limited dexterity might find this difficult, so the coding features must be large. With the disclosed system, complex codes can be aligned automatically, no matter in what orientation the user inserts the cartridge into the holder.
  • the disclosed coding and alignment system may also result in a low cost coding mechanism since the system does not require a large number of independent parts and can be manufactured in a cost effective manner. Moreover, there are quite a large number of different coding configurations between the interface and the cartridge holder that may be used. Consequently, with the disclosed coding and alignment system, a large number of medicaments can be distinguished from one another. In addition, with the disclosed coding and alignment system, if a user attempts to load an incorrect reservoir into a cartridge holder designed for a different cartridge, the user will be alerted at an early stage of the assembly process.
  • first coding feature 1203 outer surface 1204 coding element 1206 coding element 1208 coding element 1220 drug reservoir 1222 vessel

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La présente invention concerne une interface (306) pour coder un réservoir (120) destiné à un dispositif de distribution de médicament (1108, 100). L'interface (306) comprend un premier élément de codage (294, 296). Un élément de codage correspondant (302, 304) est disposé dans le dispositif de distribution de médicament (1108, 100). Le premier élément de codage (294, 296) coopère avec l'élément de codage correspondant (302, 304) disposé sur le dispositif de distribution de médicament (1108, 100) de manière à permettre que le réservoir (120) fonctionne avec le dispositif de distribution de médicament (1108, 100).
PCT/EP2011/056476 2010-04-23 2011-04-21 Dispositif de distribution de médicament et réservoir à médicament présentant un mécanisme de codage mécanique Ceased WO2011131779A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32728610P 2010-04-23 2010-04-23
US61/327,286 2010-04-23
EP10171166.1 2010-07-29
EP10171166 2010-07-29

Publications (1)

Publication Number Publication Date
WO2011131779A1 true WO2011131779A1 (fr) 2011-10-27

Family

ID=43432080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/056476 Ceased WO2011131779A1 (fr) 2010-04-23 2011-04-21 Dispositif de distribution de médicament et réservoir à médicament présentant un mécanisme de codage mécanique

Country Status (1)

Country Link
WO (1) WO2011131779A1 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085017A3 (fr) * 2010-12-22 2012-12-20 Sanofi-Aventis Deutschland Gmbh Cartouche spécialisée
WO2013152861A1 (fr) * 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Nébuliseur doté de moyens de codage
US8834449B2 (en) 2012-01-23 2014-09-16 Ikomed Technologies, Inc. Mixing syringe
JP2015517847A (ja) * 2012-04-26 2015-06-25 アルコン リサーチ， リミテッド 灌流源識別システム
US9682202B2 (en) 2009-05-18 2017-06-20 Boehringer Ingelheim International Gmbh Adapter, inhalation device, and atomizer
US9724482B2 (en) 2009-11-25 2017-08-08 Boehringer Ingelheim International Gmbh Nebulizer
US9744313B2 (en) 2013-08-09 2017-08-29 Boehringer Ingelheim International Gmbh Nebulizer
US9751056B2 (en) 2012-01-23 2017-09-05 Merit Medical Systems, Inc. Mixing syringe
US9757750B2 (en) 2011-04-01 2017-09-12 Boehringer Ingelheim International Gmbh Medicinal device with container
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
US10004857B2 (en) 2013-08-09 2018-06-26 Boehringer Ingelheim International Gmbh Nebulizer
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
US10099022B2 (en) 2014-05-07 2018-10-16 Boehringer Ingelheim International Gmbh Nebulizer
US10124129B2 (en) 2008-01-02 2018-11-13 Boehringer Ingelheim International Gmbh Dispensing device, storage device and method for dispensing a formulation
US10124125B2 (en) 2009-11-25 2018-11-13 Boehringer Ingelheim International Gmbh Nebulizer
US10195374B2 (en) 2014-05-07 2019-02-05 Boehringer Ingelheim International Gmbh Container, nebulizer and use
WO2020008202A1 (fr) * 2018-07-05 2020-01-09 Owen Mumford Limited Agencements d'emballage de médicament
EP3597236A1 (fr) * 2018-07-18 2020-01-22 Sanofi Ensemble cartouche pour dispositif d'administration de médicament et son procédé d'assemblage
EP3597239A1 (fr) * 2018-07-18 2020-01-22 Sanofi Système pour dispositif d'administration de médicaments
US10722666B2 (en) 2014-05-07 2020-07-28 Boehringer Ingelheim International Gmbh Nebulizer with axially movable and lockable container and indicator
USD907193S1 (en) 2018-02-21 2021-01-05 Eli Lilly And Company Secured medication transfer set
US11103640B2 (en) 2012-02-24 2021-08-31 Novo Nordisk A/S Drug delivery device with front loading feature
US11123490B2 (en) 2012-08-08 2021-09-21 Sanofi-Aventis Deutschland Gmbh Drug delivery device with tamper-evident closure
RU2776138C1 (ru) * 2018-07-18 2022-07-14 Санофи Система для устройства доставки лекарственного средства
WO2022233757A1 (fr) * 2021-05-03 2022-11-10 Sanofi Composants de corps et contenant pour médicament pour un dispositif d'injection
US11730678B2 (en) 2016-08-22 2023-08-22 Eli Lilly And Company Secured medication transfer system

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20110690U1 (de) * 2001-06-27 2001-09-13 Spyra, Heinrich, 91056 Erlangen Verwechslungsschutz zur Verhinderung von Bestückung einer Injektionshilfe mit einer falschen Medikamentenampulle
WO2003017915A1 (fr) * 2001-08-27 2003-03-06 Novo Nordisk A/S Cartouche et systeme medical de distribution accueillant une telle cartouche
US20060027233A1 (en) * 2004-02-24 2006-02-09 Boehringer Ingelheim International Gmbh Nebulizer
WO2008009645A1 (fr) * 2006-07-15 2008-01-24 Novo Nordisk A/S Système d'administration médicale présentant des moyens de codage asymétrique
WO2008059063A1 (fr) * 2006-11-17 2008-05-22 Novo Nordisk A/S Système d'administration médical comprenant un mécanisme de codage
WO2010006870A1 (fr) * 2008-07-15 2010-01-21 Shl Group Ab Dispositif d'administration de médicament

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20110690U1 (de) * 2001-06-27 2001-09-13 Spyra, Heinrich, 91056 Erlangen Verwechslungsschutz zur Verhinderung von Bestückung einer Injektionshilfe mit einer falschen Medikamentenampulle
WO2003017915A1 (fr) * 2001-08-27 2003-03-06 Novo Nordisk A/S Cartouche et systeme medical de distribution accueillant une telle cartouche
US20060027233A1 (en) * 2004-02-24 2006-02-09 Boehringer Ingelheim International Gmbh Nebulizer
WO2008009645A1 (fr) * 2006-07-15 2008-01-24 Novo Nordisk A/S Système d'administration médicale présentant des moyens de codage asymétrique
WO2008059063A1 (fr) * 2006-11-17 2008-05-22 Novo Nordisk A/S Système d'administration médical comprenant un mécanisme de codage
WO2010006870A1 (fr) * 2008-07-15 2010-01-21 Shl Group Ab Dispositif d'administration de médicament

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1985, MARK PUBLISHING COMPANY

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10124129B2 (en) 2008-01-02 2018-11-13 Boehringer Ingelheim International Gmbh Dispensing device, storage device and method for dispensing a formulation
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
US9682202B2 (en) 2009-05-18 2017-06-20 Boehringer Ingelheim International Gmbh Adapter, inhalation device, and atomizer
US10124125B2 (en) 2009-11-25 2018-11-13 Boehringer Ingelheim International Gmbh Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
US9724482B2 (en) 2009-11-25 2017-08-08 Boehringer Ingelheim International Gmbh Nebulizer
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
WO2012085017A3 (fr) * 2010-12-22 2012-12-20 Sanofi-Aventis Deutschland Gmbh Cartouche spécialisée
US10195345B2 (en) 2010-12-22 2019-02-05 Sanofi-Aventis Deutschland Gmbh Dedicated cartridge
US9757750B2 (en) 2011-04-01 2017-09-12 Boehringer Ingelheim International Gmbh Medicinal device with container
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
US9751056B2 (en) 2012-01-23 2017-09-05 Merit Medical Systems, Inc. Mixing syringe
US8834449B2 (en) 2012-01-23 2014-09-16 Ikomed Technologies, Inc. Mixing syringe
US11103640B2 (en) 2012-02-24 2021-08-31 Novo Nordisk A/S Drug delivery device with front loading feature
WO2013152861A1 (fr) * 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Nébuliseur doté de moyens de codage
WO2013152894A1 (fr) * 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Pulvérisateur comprenant des moyens de détrompage
US9545487B2 (en) 2012-04-13 2017-01-17 Boehringer Ingelheim International Gmbh Dispenser with encoding means
US10220163B2 (en) 2012-04-13 2019-03-05 Boehringer Ingelheim International Gmbh Nebuliser with coding means
JP2015517847A (ja) * 2012-04-26 2015-06-25 アルコン リサーチ， リミテッド 灌流源識別システム
EP4501376A3 (fr) * 2012-08-08 2025-04-16 Sanofi-Aventis Deutschland GmbH Dispositif d'administration de médicament avec fermeture anti-sabotage
US11123490B2 (en) 2012-08-08 2021-09-21 Sanofi-Aventis Deutschland Gmbh Drug delivery device with tamper-evident closure
EP2882478B1 (fr) * 2012-08-08 2024-12-11 Sanofi-Aventis Deutschland GmbH Dispositif d'administration de médicament avec fermeture anti-sabotage
US9744313B2 (en) 2013-08-09 2017-08-29 Boehringer Ingelheim International Gmbh Nebulizer
US10004857B2 (en) 2013-08-09 2018-06-26 Boehringer Ingelheim International Gmbh Nebulizer
US11642476B2 (en) 2013-08-09 2023-05-09 Boehringer Ingelheim International Gmbh Nebulizer
US10894134B2 (en) 2013-08-09 2021-01-19 Boehringer Ingelheim International Gmbh Nebulizer
US10716905B2 (en) 2014-02-23 2020-07-21 Boehringer Lngelheim International Gmbh Container, nebulizer and use
US10722666B2 (en) 2014-05-07 2020-07-28 Boehringer Ingelheim International Gmbh Nebulizer with axially movable and lockable container and indicator
US10195374B2 (en) 2014-05-07 2019-02-05 Boehringer Ingelheim International Gmbh Container, nebulizer and use
US10099022B2 (en) 2014-05-07 2018-10-16 Boehringer Ingelheim International Gmbh Nebulizer
US12336966B2 (en) 2016-08-22 2025-06-24 Eli Lilly And Company Secured medication transfer system
US11730678B2 (en) 2016-08-22 2023-08-22 Eli Lilly And Company Secured medication transfer system
USD907193S1 (en) 2018-02-21 2021-01-05 Eli Lilly And Company Secured medication transfer set
USD997341S1 (en) 2018-02-21 2023-08-29 Eli Lilly And Company Secured medication transfer set
USD990659S1 (en) 2018-02-21 2023-06-27 Eli Lilly And Company Needle hub
WO2020008202A1 (fr) * 2018-07-05 2020-01-09 Owen Mumford Limited Agencements d'emballage de médicament
EP3597239A1 (fr) * 2018-07-18 2020-01-22 Sanofi Système pour dispositif d'administration de médicaments
RU2776138C1 (ru) * 2018-07-18 2022-07-14 Санофи Система для устройства доставки лекарственного средства
KR20210032459A (ko) * 2018-07-18 2021-03-24 사노피 약물 전달 장치용 시스템
CN112423810A (zh) * 2018-07-18 2021-02-26 赛诺菲 用于药物输送装置的药筒组件和用于组装其的方法
CN112423811A (zh) * 2018-07-18 2021-02-26 赛诺菲 用于药物递送装置的系统
CN112423811B (zh) * 2018-07-18 2024-01-09 赛诺菲 用于药物递送装置的系统
WO2020016158A1 (fr) * 2018-07-18 2020-01-23 Sanofi Ensemble cartouche pour un dispositif d'administration de médicament et son procédé d'assemblage
KR102753158B1 (ko) 2018-07-18 2025-01-14 사노피 약물 전달 장치용 시스템
WO2020016162A1 (fr) * 2018-07-18 2020-01-23 Sanofi Système pour un dispositif d'administration de médicament
EP3597236A1 (fr) * 2018-07-18 2020-01-22 Sanofi Ensemble cartouche pour dispositif d'administration de médicament et son procédé d'assemblage
US12383677B2 (en) 2018-07-18 2025-08-12 Sanofi System for a drug delivery device
US12427259B2 (en) 2018-07-18 2025-09-30 Sanofi Cartridge assembly for a drug delivery device and method for assembling the same
WO2022233757A1 (fr) * 2021-05-03 2022-11-10 Sanofi Composants de corps et contenant pour médicament pour un dispositif d'injection

Similar Documents

Publication Publication Date Title
EP2560706B1 (fr) Support de cartouche et interface d'alignement
EP2560708B1 (fr) Ensemble de cartouche codé
US10195345B2 (en) Dedicated cartridge
US9731085B2 (en) Cartridge assembly having shared fastening means and drug delivery device
EP2560705B1 (fr) Système support de cartouche codée pour un dispositif d'administration de fluides
EP2603260B1 (fr) Dispositif codé avec charnière pour connecter un réservoir de médicaments
WO2011131779A1 (fr) Dispositif de distribution de médicament et réservoir à médicament présentant un mécanisme de codage mécanique
WO2011131780A2 (fr) Virole codée pour dispositif d'administration de médicament
WO2011131777A1 (fr) Ensemble cartouche codée, mécanisme de réglage de dose, système d'administration de médicament et réservoir de médicament codé
US11904141B2 (en) Coding system for a drug delivery device and drug delivery device
DK2560705T3 (en) CODED PATTERN HOLDER SYSTEM FOR A FLUID ADMINISTRATION DEVICE
HK1182344B (en) Cartridge holder and alignment interface
HK1182344A (en) Cartridge holder and alignment interface
HK1186423B (en) Coding system for a drug delivery device and drug delivery system
HK1182343A (en) Coded cartridge assembly
HK1182343B (en) Coded cartridge assembly
HK1182341A (en) Cartridge assembly having shared fastening means and drug delivery device
HK1182341B (en) Cartridge assembly having shared fastening means and drug delivery device

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11715927

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11715927

Country of ref document: EP

Kind code of ref document: A1